Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,013Revenue $M49.0Net Margin (%)13.9Z-Score9.0
Enterprise Value $M1,025EPS $0.6Operating Margin %29.4F-Score6
P/E(ttm))144Cash Flow Per Share $0.6Pre-tax Margin (%)13.7Higher ROA y-yN
Price/Book16.210-y EBITDA Growth Rate %0Quick Ratio1.5Cash flow > EarningsY
Price/Sales19.35-y EBITDA Growth Rate %0Current Ratio1.5Lower Leverage y-yY
Price/Cash Flow32.1y-y EBITDA Growth Rate %39.0ROA % (ttm)7.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)4ROE % (ttm)14.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M20.7ROI % (ttm)10.2Gross Margin Increase y-yN

Gurus Latest Trades with LGND

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 50.14-23%New holding, 55492 sh.55,492
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 50.14-24%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 50.14-4%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 50.1411%New holding, 6136 sh.6,136
LGNDDaniel Loeb 2011-12-31 Sold Out -0.46%$10.59 - $15.73
($12.77)
$ 50.14293%Sold Out0
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 50.14280%Sold Out0
LGNDDaniel Loeb 2011-06-30 Add0.16%$9.56 - $12.02
($10.55)
$ 50.14375%Add 110.73%705,016
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 50.14375%New holding, 10000 sh.10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.06)
$ 50.14316%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.26)
$ 50.14208%New holding, 26900 sh.26,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
LGND Joel Greenblatt 2014-06-3055,4920.270.04New Buy
Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HIGGINS JOHN LPresident & CEO 2014-08-15Buy1,000$54.97-8.79view
FOEHR MATTHEW WEVP and COO 2014-06-30Buy428$43.7914.5view
Berkman Charles SVP, Gen. Counsel & Secretary 2014-06-30Buy329$43.7914.5view
Herman Melanie JDirector of Accounting 2014-06-30Buy98$43.7914.5view
Herman Melanie JDirector of Accounting 2014-06-09Sell1,100$69.68-28.04view
Berkman Charles SVP, Gen. Counsel & Secretary 2014-05-27Sell7,166$66.9-25.05view
BVF PARTNERS L P/IL 2014-03-25Sell78,226$70.09-28.46view
Davis Todd CDirector 2014-03-19Sell7,500$79.57-36.99view
LAMATTINA JOHN LDirector 2014-03-18Sell5,000$78.83-36.39view
Sabba Stephen LDirector 2014-02-27Sell500$72.25-30.6view

Press Releases about LGND :

    Quarterly/Annual Reports about LGND:

    News about LGND:

    Articles On GuruFocus.com
    Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
    5 Hot Stocks to Consider Now Mar 30 2012 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
    Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
    Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 
    Ligand to Hold Fourth Quarter Results Conference Call on February 12 Jan 29 2009 

    More From Other Websites
    Ligand Inks 2nd Captisol Deal with CURx Pharmaceuticals Sep 10 2014
    Ligand Licenses Captisol-enabled™ Lamotrigine to CURx Pharmaceuticals, Inc. Sep 09 2014
    Lemelson Capital Management Marks Flagship Fund's Second Anniversary Sep 05 2014
    Ligand Pharmaceuticals Inc Stock Downgraded (LGND) Aug 27 2014
    Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta®/Revolade™ For Use in... Aug 27 2014
    Lemelson Capital Comments on Large Institutional Selling in Shares of Ligand Pharmaceuticals Amidst... Aug 25 2014
    LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Aug 18 2014
    Ligand Up on Multi-Program Captisol Deal with Avion Pharma Aug 18 2014
    Avion Pharmaceuticals, LLC, signs Captisol® License Agreement with Ligand Pharmaceuticals to... Aug 15 2014
    Lemelson Capital Says Ligand Pharmaceuticals' $225M Debt Issuance Solidifies Company's Insolvency,... Aug 14 2014
    Ligand Signs Multi-Program Captisol® License Agreement with Avion Pharmaceuticals Aug 14 2014
    LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 13 2014
    Ligand Prices Offering of $225 Million of Convertible Senior Notes Aug 13 2014
    LIGAND PHARMACEUTICALS INC Financials Aug 12 2014
    LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 11 2014
    Ligand Announces Proposed Offering of $225 Million of Convertible Senior Notes and Announces $200... Aug 11 2014
    Exclusive: Emmanuel Lemelson Talks Ligand Pharmaceuticals Aug 07 2014
    Ligand Gains on Q2 Earnings Beat, Increases Guidance Aug 07 2014
    LIGAND PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 05 2014
    Ligand Pharmaceuticals (LGND) Jumps: Stock Up 10.1% Aug 05 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK